Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.
It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Feb 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 265 |
| CEO | Gilmore O’Neill |
Contact Details
Address: 11 Hurley Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617 401 9000 |
| Website | editasmedicine.com |
Stock Details
| Ticker Symbol | EDIT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650664 |
| CUSIP Number | 28106W103 |
| ISIN Number | US28106W1036 |
| Employer ID | 46-4097528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gilmore O'Neill M.D. | President, Chief Executive Officer and Director |
| Erick J. Lucera C.F.A., CPA | Chief Financial Officer and Executive Vice President |
| Dr. Linda C. Burkly Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Baisong Mei M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Dr. Feng Zhang Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Prof. George McDonald Church Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Gregory Whitehead | Executive Vice President and Chief Technical and Quality Officer |
| Cristi Barnett | Corporate Communications and Investor Relations |
| Charlene Stern J.D., Ph.D. | Executive Vice President and General Counsel |
| Linea Aspesi | Executive Vice President and Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 144 | Filing |
| Aug 29, 2024 | 144 | Filing |
| Aug 7, 2024 | 10-Q | Quarterly Report |